OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Isaacs Discusses the Future of Treatment for HER2+ Breast Cancer

February 14th 2018

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses the future of treatment for patients with HER2-positive breast cancer.

Dr. Flinn on Toxicities With Venetoclax Plus Obinutuzumab in CLL

February 14th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the toxicities associated with the combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL).

Dr. Ocean on the Mechanism of Action of High-Dose Vitamin C in KRAS Mutations

February 14th 2018

Allyson Ocean, MD, medical oncologist, attending physician, Gastrointestinal Oncology, Weill Cornell Medicine/NewYork-Presbyterian Hospital, medical oncologist, The Jay Monahan Center for Gastrointestinal Health, associate professor of medicine, Weill Medical College of Cornell University, discusses ongoing research on high-dose intravenous (IV) vitamin C in KRAS-mutated cells.

Dr. King Discusses Axillary Node Dissection in Breast Cancer

February 14th 2018

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses axillary node dissection in patients with breast cancer.

Dr. Sequist Discusses Combination Regimens in EGFR+ NSCLC

February 14th 2018

Lecia V. Sequist, MD, associate professor of medicine, Harvard Medical School, Mary B. Saltonstall Chair, Oncology, Massachusetts General Hospital Center, discusses combination regimens for patients with EGFR-positive non-small cell lung cancer (NCSLC).

Dr. Ruan on Long-Term Findings With Lenalidomide Plus Rituximab in MCL

February 14th 2018

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses long-term findings with lenalidomide (Revlimid) plus rituximab (Rituxan) in mantle cell lymphoma (MCL).

Dr. McCloskey Discusses IDH Inhibitors in AML

February 14th 2018

James K. McCloskey II, MD, medical oncologist, Division of Leukemia and the Adult Blood and Marrow Stem Cell Transplantation Program, John Theurer Cancer Center, discusses IDH inhibitors in acute lymphoblastic leukemia (AML).

Dr. O'Malley Discusses the Current Role of PARP Inhibitors in Ovarian Cancer

February 14th 2018

David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the current role for PARP inhibitors for patients with ovarian cancer.

Dr. Koontz Discusses LHRH in High-Risk Prostate Cancer

February 14th 2018

Bridget F. Koontz, MD, radiation oncologist, Duke Cancer Institute, discusses a phase II trial of 6 months of androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.

Dr. Pishvaian on Precision Medicine in GI Cancer

February 13th 2018

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses the use of precision medicine, specifically molecular profiling in patients with gastrointestinal (GI) cancers.

Dr. He on the Potential of Immune Checkpoint Inhibitors in GI Cancers

February 13th 2018

Aiwu Ruth He, MD, PhD, associate professor of medicine, Georgetown-Lombardi Comprehensive Cancer Center, summarizes current treatment approaches in gastrointestinal (GI) cancers.

Dr. Usmani Discusses Molecular Profiling in Myeloma

February 13th 2018

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses molecular profiling in patients with multiple myeloma.

Dr. Plimack Discusses Recent Trials in Kidney Cancer

February 13th 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses recent trials in kidney cancer.

Dr. Levy Discusses Pembrolizumab in NSCLC

February 13th 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses pembrolizumab (Keytruda) in non-small cell lung cancer.

Dr. Bellmunt on Immunotherapy Plus IDO in Urothelial Carcinoma

February 12th 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses the combination of immunotherapy with IDO inhibitors for patients with urothelial carcinoma.

Dr. Hendifar Discusses the Future Treatment of NETs

February 12th 2018

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses the future treatment landscape for patients with neuroendocrine tumors (NETs).

Dr. Mutch Discusses Radiation Versus Targeted Therapy in Endometrial Cancer

February 12th 2018

David Mutch, MD, Ira C. and Judith Gall professor, vice chair of obstetrics and gynecology, chief, Division of Gynecologic Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses whether or not a patient with high-risk endometrial cancer should receive external beam radiation therapy.

Dr. Strosberg on Radiolabeled Somatostatin Analogs in GEP-NETs

February 12th 2018

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the development of radiolabeled somatostatin analogs in the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Dr. Ocean on the Importance of Vitamin D Analogs in Pancreatic Cancer

February 12th 2018

Allyson Ocean, MD, medical oncologist, attending physician, Gastrointestinal Oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, medical oncologist, The Jay Monahan Center for Gastrointestinal Health, associate professor of medicine, Weill Medical College of Cornell University, discusses emerging anti-stromal agents in pancreatic cancer.

Dr. Morse on Managing Toxicities and Sequencing Agents in mCRC

February 12th 2018

Michael A. Morse, MD, professor, Medicine, Department of Surgery, Duke University School of Medicine, Duke Cancer Institute, discusses factors that should be taken into consideration when sequencing agents in metastatic colorectal cancer.